January 9, 2026
Nexsen (ASX:NXN) commences FDA engagement as US regulatory pathway comes into focus
Nexsen has commenced formal engagement with the US Food and Drug Administration for its GBS Rapid Sensor, marking a defined step toward US regulatory clearance under the 510(k) diagnostic pathway.
